---
id: leprosy_334
category: organisms
tags: [leprosy, Hansen-disease, Mycobacterium-leprae, paucibacillary, multibacillary, MDT, dapsone, rifampin, clofazimine]
deck: Infectious Diseases
created: 2025-01-11
modified: 2025-01-11
---

## Leprosy (Mycobacterium leprae)

**Q:** What is the WHO multidrug therapy (MDT) for paucibacillary vs multibacillary leprosy?

**A:**

**Overview:**
- **Causative agent**: *Mycobacterium leprae* (Hansen disease)
- **Transmission**: Prolonged close contact; respiratory droplets
- **Affects**: Skin, peripheral nerves, upper respiratory mucosa, eyes

**Classification:**

| Type | Ridley-Jopling | # Skin Lesions | Immune Response | Bacterial Load |
|------|----------------|----------------|-----------------|----------------|
| **Paucibacillary (PB)** | Tuberculoid (TT), Borderline tuberculoid (BT) | **≤5 lesions** | **Strong** (granulomas) | **Low** |
| **Multibacillary (MB)** | Borderline (BB), Borderline lepromatous (BL), Lepromatous (LL) | **>5 lesions** | **Weak** | **High** |

**Clinical Features:**
- **Skin lesions**: Hypopigmented or erythematous patches/plaques with **loss of sensation**
- **Nerve involvement**: Peripheral neuropathy, nerve thickening, claw hand, foot drop
- **Lepromatous (MB)**: Leonine facies, nasal septal perforation, loss of eyebrows

**WHO Multidrug Therapy (MDT):**

**Paucibacillary (PB):**
- **Rifampin 600 mg monthly** (supervised)
- **Dapsone 100 mg daily** (self-administered)
- **Duration**: **6 months**

**Multibacillary (MB):**
- **Rifampin 600 mg monthly** (supervised)
- **Clofazimine 300 mg monthly** (supervised) + 50 mg daily (self-administered)
- **Dapsone 100 mg daily** (self-administered)
- **Duration**: **12 months** (WHO); traditionally 12-24 months

**Alternative Regimen (US - NHDP):**
- **RMM**: Rifampin + Moxifloxacin + Minocycline
- Used for dapsone/clofazimine intolerance or resistance
- **2024**: 213 US patients treated with RMM

**Reactions:**

**Type 1 (Reversal Reaction):**
- **Upgrading** immune response → inflammation of existing lesions
- Treatment: **Corticosteroids** (prednisone)

**Type 2 (Erythema Nodosum Leprosum - ENL):**
- **Immune complex deposition** → painful nodules, fever, neuritis
- Treatment: **Thalidomide** (teratogenic; REMS program) or corticosteroids

**Key Points:**
- **PB**: ≤5 lesions; rifampin + dapsone × 6 months
- **MB**: >5 lesions; rifampin + clofazimine + dapsone × 12 months
- **Loss of sensation** in skin lesions = hallmark
- MDT very effective (high cure rate, low relapse)

**Mnemonic - "PB = Patch Bacilli few (6 months), MB = Many Bacilli (12 months + Clofazimine)"**

**Pearl:** Leprosy classification: ≤5 lesions = paucibacillary (PB), >5 = multibacillary (MB). MDT for PB is 6 months (rifampin + dapsone); MB is 12 months (add clofazimine). Loss of sensation in skin lesions is pathognomonic for leprosy.

**Media:**

**Sources:** [WHO Leprosy Fact Sheet 2024], [HRSA Hansen Disease Treatment], [PMC5786388 - Leprosy MDT], [Frontiers ROM vs MDT 2024]
